Treatment relative effect with 95% CI; and degree of certainty (adaptated from GRADE). method
| Treament | Trials | |||||
|---|---|---|---|---|---|---|
| clinical deterioration | clinical improvement | deaths | viral clearance | |||
| Nuvaxovid (NVX-CoV2373) Novavax | - | - | - | - | ||
| Anhui Zhifei Longcom | 0 | - | - | - | - | |
| CoVax-19 SpikoGen | 0 | - | - | - | - | |
| Sanofi/GSK recombinant protein vaccine | 0 | - | - | - | - | |
| SCB-2019 | 0 | - | - | - | - | |